Literature DB >> 18156431

Reduction of E-cadherin expression is associated with non-lobular breast carcinomas of basal-like and triple negative phenotype.

B Mahler-Araujo1, K Savage, S Parry, J S Reis-Filho.   

Abstract

AIM: E-cadherin inactivation in breast cancer has been shown to be strongly associated with lobular breast cancer. However, little is known about the levels of E-cadherin expression according to the breast cancer "molecular" subtypes. The aim of this study was to address the distribution of E-cadherin expression according to the different molecular subtypes of breast cancer.
METHODS: E-cadherin expression was immunohistochemically analysed in a tissue microarray containing duplicate cores of 245 invasive breast carcinomas, of which 182 cases were of non-lobular histology, using a semi-quantitative scoring system based on the percentage of cells showing membrane immunopositivity.
RESULTS: In non-lobular breast carcinomas, reduced and/or negative E-cadherin expression was significantly associated with lack of oestrogen receptor expression, low levels of CCND1 expression, positivity for cytokeratins 5/6 and 17, epidermal growth factor receptor and caveolins 1 and 2, p53 expression, high MIB-1 proliferation indices, basal-like phenotype and triple negative phenotype.
CONCLUSION: This study demonstrates that in the group of non-lobular breast cancers, reduction/lack of E-cadherin expression is preferentially found in basal-like breast carcinomas.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18156431     DOI: 10.1136/jcp.2007.053991

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  28 in total

1.  The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer.

Authors:  Dabei Tang; Shanqi Xu; Qingyuan Zhang; Wenhui Zhao
Journal:  Med Oncol       Date:  2011-04-26       Impact factor: 3.064

2.  G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer.

Authors:  Chenfang Dong; Yadi Wu; Jun Yao; Yifan Wang; Yinhua Yu; Piotr G Rychahou; B Mark Evers; Binhua P Zhou
Journal:  J Clin Invest       Date:  2012-03-12       Impact factor: 14.808

3.  The genetic landscape of breast carcinomas with neuroendocrine differentiation.

Authors:  Caterina Marchiò; Felipe C Geyer; Charlotte Ky Ng; Salvatore Piscuoglio; Maria R De Filippo; Marco Cupo; Anne M Schultheis; Raymond S Lim; Kathleen A Burke; Elena Guerini-Rocco; Mauro Papotti; Larry Norton; Anna Sapino; Britta Weigelt; Jorge S Reis-Filho
Journal:  J Pathol       Date:  2016-12-26       Impact factor: 7.996

4.  Biomarkers for EMT and MET in breast cancer: An update.

Authors:  Fei Liu; Li-Na Gu; Bao-En Shan; Cui-Zhi Geng; Mei-Xiang Sang
Journal:  Oncol Lett       Date:  2016-11-08       Impact factor: 2.967

5.  E-Cadherin and Syndecan-1 Expression in Patients With Advanced Non-small Cell Lung Cancer Treated With Chemoradiotherapy.

Authors:  Pinelopi Gkogkou; Evangelia Peponi; Dimitrios Ntaskagiannis; Samuel Murray; Asimo Demou; Ioannis Sainis; Elli Ioakeim; Evangelos Briasoulis; Pericles Tsekeris
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

Review 6.  ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches.

Authors:  Jin-Qiang Chen; Jose Russo
Journal:  Biochim Biophys Acta       Date:  2009-06-13

7.  Loss of the Metastasis Suppressor NME1, But Not of Its Highly Related Isoform NME2, Induces a Hybrid Epithelial-Mesenchymal State in Cancer Cells.

Authors:  Anda Huna; Béatrice Nawrocki-Raby; Teresita Padilla-Benavides; Julie Gavard; Sylvie Coscoy; David Bernard; Mathieu Boissan
Journal:  Int J Mol Sci       Date:  2021-04-02       Impact factor: 5.923

8.  Py2T murine breast cancer cells, a versatile model of TGFβ-induced EMT in vitro and in vivo.

Authors:  Lorenz Waldmeier; Nathalie Meyer-Schaller; Maren Diepenbruck; Gerhard Christofori
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

9.  APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer.

Authors:  Rachel Brough; Ilirjana Bajrami; Radost Vatcheva; Rachael Natrajan; Jorge S Reis-Filho; Christopher J Lord; Alan Ashworth
Journal:  EMBO J       Date:  2012-01-31       Impact factor: 11.598

10.  Immunophenotypes of glycogen rich clear cell carcinoma.

Authors:  Sung Eun Kim; Ja Seung Koo; Woo-Hee Jung
Journal:  Yonsei Med J       Date:  2012-11-01       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.